JP2013508415A - 癌の免疫療法、および治療の方法 - Google Patents
癌の免疫療法、および治療の方法 Download PDFInfo
- Publication number
- JP2013508415A JP2013508415A JP2012535437A JP2012535437A JP2013508415A JP 2013508415 A JP2013508415 A JP 2013508415A JP 2012535437 A JP2012535437 A JP 2012535437A JP 2012535437 A JP2012535437 A JP 2012535437A JP 2013508415 A JP2013508415 A JP 2013508415A
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- immunogen
- patient
- treatment
- psma
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 title claims abstract description 143
- 238000011282 treatment Methods 0.000 title claims description 142
- 238000002619 cancer immunotherapy Methods 0.000 title description 2
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 249
- 102000036639 antigens Human genes 0.000 claims abstract description 215
- 108091007433 antigens Proteins 0.000 claims abstract description 215
- 239000000427 antigen Substances 0.000 claims abstract description 213
- 238000009169 immunotherapy Methods 0.000 claims abstract description 152
- 201000011510 cancer Diseases 0.000 claims abstract description 102
- 201000010099 disease Diseases 0.000 claims description 98
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 98
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 94
- 101000892862 Homo sapiens Glutamate carboxypeptidase 2 Proteins 0.000 claims description 92
- 230000002163 immunogen Effects 0.000 claims description 91
- 102100041003 Glutamate carboxypeptidase 2 Human genes 0.000 claims description 89
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 88
- 102000036673 PRAME Human genes 0.000 claims description 86
- 108060006580 PRAME Proteins 0.000 claims description 86
- 230000004044 response Effects 0.000 claims description 81
- 239000013612 plasmid Substances 0.000 claims description 74
- 210000004324 lymphatic system Anatomy 0.000 claims description 66
- 201000001441 melanoma Diseases 0.000 claims description 52
- 102000016200 MART-1 Antigen Human genes 0.000 claims description 43
- 108010010995 MART-1 Antigen Proteins 0.000 claims description 43
- 230000028993 immune response Effects 0.000 claims description 43
- 238000002560 therapeutic procedure Methods 0.000 claims description 41
- 206010060862 Prostate cancer Diseases 0.000 claims description 40
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 40
- 230000003308 immunostimulating effect Effects 0.000 claims description 37
- 206010027476 Metastases Diseases 0.000 claims description 35
- 102000003425 Tyrosinase Human genes 0.000 claims description 30
- 108060008724 Tyrosinase Proteins 0.000 claims description 30
- 210000000056 organ Anatomy 0.000 claims description 30
- 239000003795 chemical substances by application Substances 0.000 claims description 28
- 239000003814 drug Substances 0.000 claims description 28
- 208000018501 Lymphatic disease Diseases 0.000 claims description 26
- 230000005867 T cell response Effects 0.000 claims description 26
- 230000035755 proliferation Effects 0.000 claims description 26
- 229960001438 immunostimulant agent Drugs 0.000 claims description 25
- 239000003022 immunostimulating agent Substances 0.000 claims description 25
- 208000018555 lymphatic system disease Diseases 0.000 claims description 25
- 230000008685 targeting Effects 0.000 claims description 23
- 210000001519 tissue Anatomy 0.000 claims description 23
- 239000012636 effector Substances 0.000 claims description 22
- 238000003556 assay Methods 0.000 claims description 21
- 210000003162 effector t lymphocyte Anatomy 0.000 claims description 21
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 20
- 206010038389 Renal cancer Diseases 0.000 claims description 20
- 201000010982 kidney cancer Diseases 0.000 claims description 20
- 229920001481 poly(stearyl methacrylate) Polymers 0.000 claims description 20
- 238000012216 screening Methods 0.000 claims description 20
- 230000009401 metastasis Effects 0.000 claims description 18
- 102000002689 Toll-like receptor Human genes 0.000 claims description 17
- 108020000411 Toll-like receptor Proteins 0.000 claims description 17
- 102000004127 Cytokines Human genes 0.000 claims description 16
- 108090000695 Cytokines Proteins 0.000 claims description 16
- 208000005017 glioblastoma Diseases 0.000 claims description 16
- 108090000623 proteins and genes Proteins 0.000 claims description 16
- 229940079593 drug Drugs 0.000 claims description 15
- 230000001024 immunotherapeutic effect Effects 0.000 claims description 14
- 238000011510 Elispot assay Methods 0.000 claims description 13
- 238000004458 analytical method Methods 0.000 claims description 13
- 230000036039 immunity Effects 0.000 claims description 13
- -1 respectively Proteins 0.000 claims description 13
- 239000003446 ligand Substances 0.000 claims description 12
- 102000007863 pattern recognition receptors Human genes 0.000 claims description 12
- 108010089193 pattern recognition receptors Proteins 0.000 claims description 12
- 208000017520 skin disease Diseases 0.000 claims description 12
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 11
- 229940046168 CpG oligodeoxynucleotide Drugs 0.000 claims description 11
- 208000006265 Renal cell carcinoma Diseases 0.000 claims description 11
- 238000003114 enzyme-linked immunosorbent spot assay Methods 0.000 claims description 11
- 206010006187 Breast cancer Diseases 0.000 claims description 10
- 208000026310 Breast neoplasm Diseases 0.000 claims description 10
- 239000002671 adjuvant Substances 0.000 claims description 10
- 230000001506 immunosuppresive effect Effects 0.000 claims description 10
- 230000001737 promoting effect Effects 0.000 claims description 10
- 102000025850 HLA-A2 Antigen Human genes 0.000 claims description 9
- 108010074032 HLA-A2 Antigen Proteins 0.000 claims description 9
- 230000001105 regulatory effect Effects 0.000 claims description 9
- 206010033128 Ovarian cancer Diseases 0.000 claims description 8
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 8
- 210000005212 secondary lymphoid organ Anatomy 0.000 claims description 8
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 7
- 108010012236 Chemokines Proteins 0.000 claims description 7
- 102000019034 Chemokines Human genes 0.000 claims description 7
- 108020004414 DNA Proteins 0.000 claims description 7
- 230000000139 costimulatory effect Effects 0.000 claims description 7
- 102000040650 (ribonucleotides)n+m Human genes 0.000 claims description 6
- 206010009944 Colon cancer Diseases 0.000 claims description 6
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 6
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims description 6
- 206010062904 Hormone-refractory prostate cancer Diseases 0.000 claims description 6
- 206010061252 Intraocular melanoma Diseases 0.000 claims description 6
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims description 6
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 6
- 108091023040 Transcription factor Proteins 0.000 claims description 6
- 102000040945 Transcription factor Human genes 0.000 claims description 6
- 201000005969 Uveal melanoma Diseases 0.000 claims description 6
- 201000004101 esophageal cancer Diseases 0.000 claims description 6
- 239000005556 hormone Substances 0.000 claims description 6
- 229940088597 hormone Drugs 0.000 claims description 6
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 6
- 201000002575 ocular melanoma Diseases 0.000 claims description 6
- 201000002528 pancreatic cancer Diseases 0.000 claims description 6
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 6
- 230000006641 stabilisation Effects 0.000 claims description 6
- 238000011105 stabilization Methods 0.000 claims description 6
- 206010027406 Mesothelioma Diseases 0.000 claims description 5
- 230000030741 antigen processing and presentation Effects 0.000 claims description 5
- 230000012202 endocytosis Effects 0.000 claims description 5
- 210000005210 lymphoid organ Anatomy 0.000 claims description 5
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 5
- 239000013610 patient sample Substances 0.000 claims description 5
- 208000015347 renal cell adenocarcinoma Diseases 0.000 claims description 5
- 230000011664 signaling Effects 0.000 claims description 5
- 230000001052 transient effect Effects 0.000 claims description 5
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 5
- POVNCJSPYFCWJR-USZUGGBUSA-N (4s)-4-[[(2s)-2-[[(2s)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]-4-methylpentanoyl]amino]-5-[(2s)-2-[[2-[(2s)-2-[[(2s)-1-[[(2s,3r)-1-[[(1s)-1-carboxy-2-methylpropyl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]carbamoyl]pyrrolidin-1- Chemical compound C([C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N1[C@@H](CCC1)C(=O)NCC(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(O)=O)C1=CC=C(O)C=C1 POVNCJSPYFCWJR-USZUGGBUSA-N 0.000 claims description 4
- XEDONBRPTABQFB-UHFFFAOYSA-N 4-[(2-formyl-3-hydroxyphenoxy)methyl]benzoic acid Chemical compound C1=CC(C(=O)O)=CC=C1COC1=CC=CC(O)=C1C=O XEDONBRPTABQFB-UHFFFAOYSA-N 0.000 claims description 4
- 108010077544 Chromatin Proteins 0.000 claims description 4
- 102000043129 MHC class I family Human genes 0.000 claims description 4
- 108091054437 MHC class I family Proteins 0.000 claims description 4
- 102000043131 MHC class II family Human genes 0.000 claims description 4
- 108091054438 MHC class II family Proteins 0.000 claims description 4
- 230000005775 apoptotic pathway Effects 0.000 claims description 4
- 210000003483 chromatin Anatomy 0.000 claims description 4
- 230000007423 decrease Effects 0.000 claims description 4
- 229950009795 tucaresol Drugs 0.000 claims description 4
- RHKWIGHJGOEUSM-UHFFFAOYSA-N 3h-imidazo[4,5-h]quinoline Chemical class C1=CN=C2C(N=CN3)=C3C=CC2=C1 RHKWIGHJGOEUSM-UHFFFAOYSA-N 0.000 claims description 3
- 102100030346 Antigen peptide transporter 1 Human genes 0.000 claims description 3
- 102100030343 Antigen peptide transporter 2 Human genes 0.000 claims description 3
- 101000831496 Homo sapiens Toll-like receptor 3 Proteins 0.000 claims description 3
- 108010023335 Member 2 Subfamily B ATP Binding Cassette Transporter Proteins 0.000 claims description 3
- MSFSPUZXLOGKHJ-UHFFFAOYSA-N Muraminsaeure Natural products OC(=O)C(C)OC1C(N)C(O)OC(CO)C1O MSFSPUZXLOGKHJ-UHFFFAOYSA-N 0.000 claims description 3
- 108010013639 Peptidoglycan Proteins 0.000 claims description 3
- 108091036414 Polyinosinic:polycytidylic acid Proteins 0.000 claims description 3
- 102000055027 Protein Methyltransferases Human genes 0.000 claims description 3
- 108700040121 Protein Methyltransferases Proteins 0.000 claims description 3
- 108010060818 Toll-Like Receptor 9 Proteins 0.000 claims description 3
- 102100024324 Toll-like receptor 3 Human genes 0.000 claims description 3
- 102100033117 Toll-like receptor 9 Human genes 0.000 claims description 3
- 230000000840 anti-viral effect Effects 0.000 claims description 3
- 102000015736 beta 2-Microglobulin Human genes 0.000 claims description 3
- 108010081355 beta 2-Microglobulin Proteins 0.000 claims description 3
- 230000033228 biological regulation Effects 0.000 claims description 3
- 230000030279 gene silencing Effects 0.000 claims description 3
- 102000046689 human FOLH1 Human genes 0.000 claims description 3
- 210000002865 immune cell Anatomy 0.000 claims description 3
- BXNMTOQRYBFHNZ-UHFFFAOYSA-N resiquimod Chemical compound C1=CC=CC2=C(N(C(COCC)=N3)CC(C)(C)O)C3=C(N)N=C21 BXNMTOQRYBFHNZ-UHFFFAOYSA-N 0.000 claims description 3
- 229950010550 resiquimod Drugs 0.000 claims description 3
- PIGTXFOGKFOFTO-FVFWYJKVSA-N (2S,3S,4S,5R,6R)-6-[[(3S,4S,4aR,6aR,6bS,8R,8aR,12aS,14aR,14bR)-8a-carboxy-4-formyl-8-hydroxy-4,6a,6b,11,11,14b-hexamethyl-1,2,3,4a,5,6,7,8,9,10,12,12a,14,14a-tetradecahydropicen-3-yl]oxy]-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound O([C@H]1CC[C@]2(C)[C@H]3CC=C4[C@@]([C@@]3(CC[C@H]2[C@@]1(C=O)C)C)(C)C[C@@H](O)[C@]1(CCC(C[C@H]14)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O PIGTXFOGKFOFTO-FVFWYJKVSA-N 0.000 claims description 2
- DOUYETYNHWVLEO-UHFFFAOYSA-N imiquimod Chemical compound C1=CC=CC2=C3N(CC(C)C)C=NC3=C(N)N=C21 DOUYETYNHWVLEO-UHFFFAOYSA-N 0.000 claims description 2
- 229960002751 imiquimod Drugs 0.000 claims description 2
- 210000001672 ovary Anatomy 0.000 claims 2
- 101100462972 Mus musculus Pcdh8 gene Proteins 0.000 claims 1
- 102000004245 Proteasome Endopeptidase Complex Human genes 0.000 claims 1
- 108090000708 Proteasome Endopeptidase Complex Proteins 0.000 claims 1
- 239000002955 immunomodulating agent Substances 0.000 abstract description 23
- 239000000203 mixture Substances 0.000 description 76
- 210000001165 lymph node Anatomy 0.000 description 52
- 210000004027 cell Anatomy 0.000 description 51
- 102000004196 processed proteins & peptides Human genes 0.000 description 40
- 230000003902 lesion Effects 0.000 description 36
- 238000002347 injection Methods 0.000 description 25
- 239000007924 injection Substances 0.000 description 25
- 230000006698 induction Effects 0.000 description 24
- 206010061289 metastatic neoplasm Diseases 0.000 description 24
- 230000003321 amplification Effects 0.000 description 23
- 238000003199 nucleic acid amplification method Methods 0.000 description 23
- 230000037452 priming Effects 0.000 description 23
- 150000001413 amino acids Chemical class 0.000 description 21
- 230000003053 immunization Effects 0.000 description 21
- 238000010186 staining Methods 0.000 description 19
- 238000002649 immunization Methods 0.000 description 18
- 230000001225 therapeutic effect Effects 0.000 description 18
- 102000007066 Prostate-Specific Antigen Human genes 0.000 description 16
- 108010072866 Prostate-Specific Antigen Proteins 0.000 description 16
- 230000014509 gene expression Effects 0.000 description 15
- 230000001965 increasing effect Effects 0.000 description 15
- 230000001939 inductive effect Effects 0.000 description 15
- 239000000047 product Substances 0.000 description 15
- 210000003491 skin Anatomy 0.000 description 15
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 14
- 210000000987 immune system Anatomy 0.000 description 13
- 102000004169 proteins and genes Human genes 0.000 description 13
- 238000001356 surgical procedure Methods 0.000 description 13
- 230000009278 visceral effect Effects 0.000 description 13
- 238000013461 design Methods 0.000 description 12
- 210000004881 tumor cell Anatomy 0.000 description 12
- 201000009030 Carcinoma Diseases 0.000 description 11
- 239000003153 chemical reaction reagent Substances 0.000 description 11
- 230000000694 effects Effects 0.000 description 11
- 230000001394 metastastic effect Effects 0.000 description 11
- 230000002459 sustained effect Effects 0.000 description 11
- 230000009467 reduction Effects 0.000 description 10
- 210000004369 blood Anatomy 0.000 description 9
- 239000008280 blood Substances 0.000 description 9
- 230000001976 improved effect Effects 0.000 description 9
- 229920001184 polypeptide Polymers 0.000 description 9
- 229940124597 therapeutic agent Drugs 0.000 description 9
- 206010061818 Disease progression Diseases 0.000 description 8
- 108091008874 T cell receptors Proteins 0.000 description 8
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 8
- 238000002591 computed tomography Methods 0.000 description 8
- 230000005750 disease progression Effects 0.000 description 8
- 238000001802 infusion Methods 0.000 description 8
- 210000000612 antigen-presenting cell Anatomy 0.000 description 7
- 238000011156 evaluation Methods 0.000 description 7
- 238000003384 imaging method Methods 0.000 description 7
- 230000036961 partial effect Effects 0.000 description 7
- 238000001959 radiotherapy Methods 0.000 description 7
- 229960005486 vaccine Drugs 0.000 description 7
- VGKZTCPRZPOHJD-ZEXGZJMNSA-N (2S)-2-[[2-[[(2S,3S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-3-hydroxypropanoyl]amino]pentanoyl]amino]-4-methylpentanoyl]amino]-5-oxopentanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-4-methylpentanoyl]amino]-3-methylpentanoyl]amino]acetyl]amino]hexanoic acid Chemical compound CCCC[C@@H](C(O)=O)NC(=O)CNC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC)NC(=O)[C@@H](N)CO)CC1=CN=CN1 VGKZTCPRZPOHJD-ZEXGZJMNSA-N 0.000 description 6
- 108010074328 Interferon-gamma Proteins 0.000 description 6
- XHAZJQSTGGLMLZ-MSDGEDAMSA-N N([C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(O)=O)C(=O)[C@@H]1CCCN1C(=O)[C@H](CC(C)C)NC(=O)CN Chemical compound N([C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(O)=O)C(=O)[C@@H]1CCCN1C(=O)[C@H](CC(C)C)NC(=O)CN XHAZJQSTGGLMLZ-MSDGEDAMSA-N 0.000 description 6
- 238000009098 adjuvant therapy Methods 0.000 description 6
- 230000002411 adverse Effects 0.000 description 6
- 238000002512 chemotherapy Methods 0.000 description 6
- 238000001514 detection method Methods 0.000 description 6
- 238000009472 formulation Methods 0.000 description 6
- 238000009099 neoadjuvant therapy Methods 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 102100037850 Interferon gamma Human genes 0.000 description 5
- 238000001574 biopsy Methods 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 230000000977 initiatory effect Effects 0.000 description 5
- 230000001926 lymphatic effect Effects 0.000 description 5
- 238000005259 measurement Methods 0.000 description 5
- 102000039446 nucleic acids Human genes 0.000 description 5
- 108020004707 nucleic acids Proteins 0.000 description 5
- 150000007523 nucleic acids Chemical class 0.000 description 5
- 210000002307 prostate Anatomy 0.000 description 5
- 238000002271 resection Methods 0.000 description 5
- 230000028327 secretion Effects 0.000 description 5
- 238000007920 subcutaneous administration Methods 0.000 description 5
- 230000004083 survival effect Effects 0.000 description 5
- 239000013598 vector Substances 0.000 description 5
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 4
- 230000006052 T cell proliferation Effects 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 230000004069 differentiation Effects 0.000 description 4
- 239000013604 expression vector Substances 0.000 description 4
- 230000012010 growth Effects 0.000 description 4
- 239000000367 immunologic factor Substances 0.000 description 4
- 239000003112 inhibitor Substances 0.000 description 4
- 210000004072 lung Anatomy 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 230000037361 pathway Effects 0.000 description 4
- 210000005259 peripheral blood Anatomy 0.000 description 4
- 239000011886 peripheral blood Substances 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 239000008174 sterile solution Substances 0.000 description 4
- 238000011269 treatment regimen Methods 0.000 description 4
- 102000006306 Antigen Receptors Human genes 0.000 description 3
- 108010083359 Antigen Receptors Proteins 0.000 description 3
- 108010021064 CTLA-4 Antigen Proteins 0.000 description 3
- 102000008203 CTLA-4 Antigen Human genes 0.000 description 3
- 229940045513 CTLA4 antagonist Drugs 0.000 description 3
- 241000701022 Cytomegalovirus Species 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 102000003814 Interleukin-10 Human genes 0.000 description 3
- 108090000174 Interleukin-10 Proteins 0.000 description 3
- 241000829100 Macaca mulatta polyomavirus 1 Species 0.000 description 3
- 206010061309 Neoplasm progression Diseases 0.000 description 3
- 208000007660 Residual Neoplasm Diseases 0.000 description 3
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 3
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 230000002146 bilateral effect Effects 0.000 description 3
- 239000000090 biomarker Substances 0.000 description 3
- 229940022399 cancer vaccine Drugs 0.000 description 3
- 229960000390 fludarabine Drugs 0.000 description 3
- GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 230000035876 healing Effects 0.000 description 3
- 210000001365 lymphatic vessel Anatomy 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 210000002752 melanocyte Anatomy 0.000 description 3
- 230000002688 persistence Effects 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 230000002250 progressing effect Effects 0.000 description 3
- 230000000069 prophylactic effect Effects 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 230000004043 responsiveness Effects 0.000 description 3
- 238000012552 review Methods 0.000 description 3
- 230000035945 sensitivity Effects 0.000 description 3
- 206010040882 skin lesion Diseases 0.000 description 3
- 231100000444 skin lesion Toxicity 0.000 description 3
- 150000003384 small molecules Chemical class 0.000 description 3
- 210000004872 soft tissue Anatomy 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 3
- 230000005747 tumor angiogenesis Effects 0.000 description 3
- 230000005751 tumor progression Effects 0.000 description 3
- 230000003612 virological effect Effects 0.000 description 3
- 208000037911 visceral disease Diseases 0.000 description 3
- 102100023990 60S ribosomal protein L17 Human genes 0.000 description 2
- 102100035526 B melanoma antigen 1 Human genes 0.000 description 2
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 206010015150 Erythema Diseases 0.000 description 2
- 208000010201 Exanthema Diseases 0.000 description 2
- 108700028146 Genetic Enhancer Elements Proteins 0.000 description 2
- 102000001398 Granzyme Human genes 0.000 description 2
- 108060005986 Granzyme Proteins 0.000 description 2
- 101000874316 Homo sapiens B melanoma antigen 1 Proteins 0.000 description 2
- 101000578784 Homo sapiens Melanoma antigen recognized by T-cells 1 Proteins 0.000 description 2
- 101001094545 Homo sapiens Retrotransposon-like protein 1 Proteins 0.000 description 2
- 101000984753 Homo sapiens Serine/threonine-protein kinase B-raf Proteins 0.000 description 2
- 241000701806 Human papillomavirus Species 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 108010002350 Interleukin-2 Proteins 0.000 description 2
- 102000003855 L-lactate dehydrogenase Human genes 0.000 description 2
- 108700023483 L-lactate dehydrogenases Proteins 0.000 description 2
- 208000007433 Lymphatic Metastasis Diseases 0.000 description 2
- 102100037020 Melanoma antigen preferentially expressed in tumors Human genes 0.000 description 2
- 102100028389 Melanoma antigen recognized by T-cells 1 Human genes 0.000 description 2
- 108090000744 Mitogen-Activated Protein Kinase Kinases Proteins 0.000 description 2
- 102000004232 Mitogen-Activated Protein Kinase Kinases Human genes 0.000 description 2
- 102000010292 Peptide Elongation Factor 1 Human genes 0.000 description 2
- 108010077524 Peptide Elongation Factor 1 Proteins 0.000 description 2
- 101710089372 Programmed cell death protein 1 Proteins 0.000 description 2
- 208000003251 Pruritus Diseases 0.000 description 2
- 206010037660 Pyrexia Diseases 0.000 description 2
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 2
- 108020004511 Recombinant DNA Proteins 0.000 description 2
- 102100027103 Serine/threonine-protein kinase B-raf Human genes 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 210000004100 adrenal gland Anatomy 0.000 description 2
- 230000033115 angiogenesis Effects 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 230000000890 antigenic effect Effects 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000008512 biological response Effects 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 238000009566 cancer vaccine Methods 0.000 description 2
- 230000006037 cell lysis Effects 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 229960004397 cyclophosphamide Drugs 0.000 description 2
- 210000004443 dendritic cell Anatomy 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 238000012631 diagnostic technique Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 231100000321 erythema Toxicity 0.000 description 2
- 201000005884 exanthem Diseases 0.000 description 2
- 238000011010 flushing procedure Methods 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 210000004013 groin Anatomy 0.000 description 2
- 238000001794 hormone therapy Methods 0.000 description 2
- 230000002519 immonomodulatory effect Effects 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 230000008595 infiltration Effects 0.000 description 2
- 238000001764 infiltration Methods 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 238000011221 initial treatment Methods 0.000 description 2
- 230000015788 innate immune response Effects 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 230000010354 integration Effects 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 210000002751 lymph Anatomy 0.000 description 2
- 210000004880 lymph fluid Anatomy 0.000 description 2
- 238000002595 magnetic resonance imaging Methods 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 239000003607 modifier Substances 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 210000004940 nucleus Anatomy 0.000 description 2
- 238000011275 oncology therapy Methods 0.000 description 2
- 206010033675 panniculitis Diseases 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 229920003023 plastic Polymers 0.000 description 2
- 230000008488 polyadenylation Effects 0.000 description 2
- 238000002600 positron emission tomography Methods 0.000 description 2
- 230000002062 proliferating effect Effects 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 206010037844 rash Diseases 0.000 description 2
- 210000003289 regulatory T cell Anatomy 0.000 description 2
- 210000001625 seminal vesicle Anatomy 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 210000002536 stromal cell Anatomy 0.000 description 2
- 210000004304 subcutaneous tissue Anatomy 0.000 description 2
- 101150047061 tag-72 gene Proteins 0.000 description 2
- 230000004614 tumor growth Effects 0.000 description 2
- 210000003171 tumor-infiltrating lymphocyte Anatomy 0.000 description 2
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 description 2
- 239000005483 tyrosine kinase inhibitor Substances 0.000 description 2
- 210000005166 vasculature Anatomy 0.000 description 2
- 201000010653 vesiculitis Diseases 0.000 description 2
- 210000001835 viscera Anatomy 0.000 description 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- KKVYYGGCHJGEFJ-UHFFFAOYSA-N 1-n-(4-chlorophenyl)-6-methyl-5-n-[3-(7h-purin-6-yl)pyridin-2-yl]isoquinoline-1,5-diamine Chemical compound N=1C=CC2=C(NC=3C(=CC=CN=3)C=3C=4N=CNC=4N=CN=3)C(C)=CC=C2C=1NC1=CC=C(Cl)C=C1 KKVYYGGCHJGEFJ-UHFFFAOYSA-N 0.000 description 1
- WEVYNIUIFUYDGI-UHFFFAOYSA-N 3-[6-[4-(trifluoromethoxy)anilino]-4-pyrimidinyl]benzamide Chemical compound NC(=O)C1=CC=CC(C=2N=CN=C(NC=3C=CC(OC(F)(F)F)=CC=3)C=2)=C1 WEVYNIUIFUYDGI-UHFFFAOYSA-N 0.000 description 1
- 101710163573 5-hydroxyisourate hydrolase Proteins 0.000 description 1
- 102100030840 AT-rich interactive domain-containing protein 4B Human genes 0.000 description 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 1
- 102000015735 Beta-catenin Human genes 0.000 description 1
- 108060000903 Beta-catenin Proteins 0.000 description 1
- 102100021943 C-C motif chemokine 2 Human genes 0.000 description 1
- 101710155857 C-C motif chemokine 2 Proteins 0.000 description 1
- 102100036848 C-C motif chemokine 20 Human genes 0.000 description 1
- 102100031102 C-C motif chemokine 4 Human genes 0.000 description 1
- 101710155855 C-C motif chemokine 4 Proteins 0.000 description 1
- 102100032367 C-C motif chemokine 5 Human genes 0.000 description 1
- 102100032366 C-C motif chemokine 7 Human genes 0.000 description 1
- 101710155834 C-C motif chemokine 7 Proteins 0.000 description 1
- PIGTXFOGKFOFTO-PPEDVFHSSA-N CC1(C)CC[C@@]2([C@H](O)C[C@]3(C)C(=CC[C@@H]4[C@@]5(C)CCC(O[C@@H]6O[C@@H]([C@@H](O)[C@H](O)[C@H]6O)C(O)=O)[C@@](C)(C=O)[C@@H]5CC[C@@]34C)[C@@H]2C1)C(O)=O Chemical compound CC1(C)CC[C@@]2([C@H](O)C[C@]3(C)C(=CC[C@@H]4[C@@]5(C)CCC(O[C@@H]6O[C@@H]([C@@H](O)[C@H](O)[C@H]6O)C(O)=O)[C@@](C)(C=O)[C@@H]5CC[C@@]34C)[C@@H]2C1)C(O)=O PIGTXFOGKFOFTO-PPEDVFHSSA-N 0.000 description 1
- 101150013553 CD40 gene Proteins 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 108010083700 Chemokine CCL20 Proteins 0.000 description 1
- 108010055166 Chemokine CCL5 Proteins 0.000 description 1
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 208000037845 Cutaneous squamous cell carcinoma Diseases 0.000 description 1
- 108010072210 Cyclophilin C Proteins 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 108010041986 DNA Vaccines Proteins 0.000 description 1
- 230000007067 DNA methylation Effects 0.000 description 1
- 229940021995 DNA vaccine Drugs 0.000 description 1
- 101100481408 Danio rerio tie2 gene Proteins 0.000 description 1
- 206010061819 Disease recurrence Diseases 0.000 description 1
- 102000018651 Epithelial Cell Adhesion Molecule Human genes 0.000 description 1
- 108010066687 Epithelial Cell Adhesion Molecule Proteins 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 102000007665 Extracellular Signal-Regulated MAP Kinases Human genes 0.000 description 1
- 108010007457 Extracellular Signal-Regulated MAP Kinases Proteins 0.000 description 1
- 102100028073 Fibroblast growth factor 5 Human genes 0.000 description 1
- 108090000380 Fibroblast growth factor 5 Proteins 0.000 description 1
- 102100039717 G antigen 1 Human genes 0.000 description 1
- 101710113436 GTPase KRas Proteins 0.000 description 1
- 102100040510 Galectin-3-binding protein Human genes 0.000 description 1
- 101710197901 Galectin-3-binding protein Proteins 0.000 description 1
- 201000010915 Glioblastoma multiforme Diseases 0.000 description 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 1
- 102000008949 Histocompatibility Antigens Class I Human genes 0.000 description 1
- 108010088652 Histocompatibility Antigens Class I Proteins 0.000 description 1
- 101000792935 Homo sapiens AT-rich interactive domain-containing protein 4B Proteins 0.000 description 1
- 101000886137 Homo sapiens G antigen 1 Proteins 0.000 description 1
- 101000934372 Homo sapiens Macrosialin Proteins 0.000 description 1
- 101001095088 Homo sapiens Melanoma antigen preferentially expressed in tumors Proteins 0.000 description 1
- 101100137533 Homo sapiens PRAME gene Proteins 0.000 description 1
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 1
- 101001062222 Homo sapiens Receptor-binding cancer antigen expressed on SiSo cells Proteins 0.000 description 1
- 101000973629 Homo sapiens Ribosome quality control complex subunit NEMF Proteins 0.000 description 1
- 101001059454 Homo sapiens Serine/threonine-protein kinase MARK2 Proteins 0.000 description 1
- 101000713602 Homo sapiens T-box transcription factor TBX21 Proteins 0.000 description 1
- 101000669402 Homo sapiens Toll-like receptor 7 Proteins 0.000 description 1
- 101000671653 Homo sapiens U3 small nucleolar RNA-associated protein 14 homolog A Proteins 0.000 description 1
- 101000851007 Homo sapiens Vascular endothelial growth factor receptor 2 Proteins 0.000 description 1
- 241000701109 Human adenovirus 2 Species 0.000 description 1
- 108010052919 Hydroxyethylthiazole kinase Proteins 0.000 description 1
- 108010027436 Hydroxymethylpyrimidine kinase Proteins 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 108010030506 Integrin alpha6beta4 Proteins 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108090001007 Interleukin-8 Proteins 0.000 description 1
- 102000004890 Interleukin-8 Human genes 0.000 description 1
- 102000017578 LAG3 Human genes 0.000 description 1
- 101150030213 Lag3 gene Proteins 0.000 description 1
- 108091054455 MAP kinase family Proteins 0.000 description 1
- 102000043136 MAP kinase family Human genes 0.000 description 1
- 102100025136 Macrosialin Human genes 0.000 description 1
- 206010027480 Metastatic malignant melanoma Diseases 0.000 description 1
- 101100381978 Mus musculus Braf gene Proteins 0.000 description 1
- 101000969137 Mus musculus Metallothionein-1 Proteins 0.000 description 1
- 101100481410 Mus musculus Tek gene Proteins 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 1
- 102000010168 Myeloid Differentiation Factor 88 Human genes 0.000 description 1
- 108010077432 Myeloid Differentiation Factor 88 Proteins 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- YZDJQTHVDDOVHR-UHFFFAOYSA-N PLX-4720 Chemical compound CCCS(=O)(=O)NC1=CC=C(F)C(C(=O)C=2C3=CC(Cl)=CN=C3NC=2)=C1F YZDJQTHVDDOVHR-UHFFFAOYSA-N 0.000 description 1
- 102100024968 Peptidyl-prolyl cis-trans isomerase C Human genes 0.000 description 1
- 102100026918 Phospholipase A2 Human genes 0.000 description 1
- 101710096328 Phospholipase A2 Proteins 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 101000621511 Potato virus M (strain German) RNA silencing suppressor Proteins 0.000 description 1
- 101710100968 Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 1
- 102100029165 Receptor-binding cancer antigen expressed on SiSo cells Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 102100022213 Ribosome quality control complex subunit NEMF Human genes 0.000 description 1
- 102100028904 Serine/threonine-protein kinase MARK2 Human genes 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 101710143177 Synaptonemal complex protein 1 Proteins 0.000 description 1
- 102100036234 Synaptonemal complex protein 1 Human genes 0.000 description 1
- 230000024932 T cell mediated immunity Effects 0.000 description 1
- 102100036840 T-box transcription factor TBX21 Human genes 0.000 description 1
- 101150031162 TM4SF1 gene Proteins 0.000 description 1
- 101800000849 Tachykinin-associated peptide 2 Proteins 0.000 description 1
- 239000004809 Teflon Substances 0.000 description 1
- 229920006362 Teflon® Polymers 0.000 description 1
- 102100039390 Toll-like receptor 7 Human genes 0.000 description 1
- 102100034902 Transmembrane 4 L6 family member 1 Human genes 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 description 1
- 102100040099 U3 small nucleolar RNA-associated protein 14 homolog A Human genes 0.000 description 1
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 238000011360 adjunctive therapy Methods 0.000 description 1
- 102000013529 alpha-Fetoproteins Human genes 0.000 description 1
- 108010026331 alpha-Fetoproteins Proteins 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 208000003373 basosquamous carcinoma Diseases 0.000 description 1
- 230000001851 biosynthetic effect Effects 0.000 description 1
- 238000001815 biotherapy Methods 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 238000007469 bone scintigraphy Methods 0.000 description 1
- 108010006025 bovine growth hormone Proteins 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 230000020411 cell activation Effects 0.000 description 1
- 238000001516 cell proliferation assay Methods 0.000 description 1
- 230000007969 cellular immunity Effects 0.000 description 1
- 230000004640 cellular pathway Effects 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 230000014564 chemokine production Effects 0.000 description 1
- 229910052804 chromium Inorganic materials 0.000 description 1
- 239000011651 chromium Substances 0.000 description 1
- 230000004186 co-expression Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000009260 cross reactivity Effects 0.000 description 1
- 238000011498 curative surgery Methods 0.000 description 1
- 230000016396 cytokine production Effects 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000007402 cytotoxic response Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 230000002222 downregulating effect Effects 0.000 description 1
- 230000007783 downstream signaling Effects 0.000 description 1
- 229960004679 doxorubicin Drugs 0.000 description 1
- 238000007876 drug discovery Methods 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000002121 endocytic effect Effects 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 238000010195 expression analysis Methods 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 230000008175 fetal development Effects 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 108700014844 flt3 ligand Proteins 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 229940044627 gamma-interferon Drugs 0.000 description 1
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 1
- 229960005277 gemcitabine Drugs 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 210000004408 hybridoma Anatomy 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000000899 immune system response Effects 0.000 description 1
- 230000006058 immune tolerance Effects 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 229940047124 interferons Drugs 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000005228 liver tissue Anatomy 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 239000008176 lyophilized powder Substances 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 208000021039 metastatic melanoma Diseases 0.000 description 1
- 238000012737 microarray-based gene expression Methods 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000002991 molded plastic Substances 0.000 description 1
- 238000012243 multiplex automated genomic engineering Methods 0.000 description 1
- PUPNJSIFIXXJCH-UHFFFAOYSA-N n-(4-hydroxyphenyl)-2-(1,1,3-trioxo-1,2-benzothiazol-2-yl)acetamide Chemical compound C1=CC(O)=CC=C1NC(=O)CN1S(=O)(=O)C2=CC=CC=C2C1=O PUPNJSIFIXXJCH-UHFFFAOYSA-N 0.000 description 1
- AEMBWNDIEFEPTH-UHFFFAOYSA-N n-tert-butyl-n-ethylnitrous amide Chemical compound CCN(N=O)C(C)(C)C AEMBWNDIEFEPTH-UHFFFAOYSA-N 0.000 description 1
- 210000001020 neural plate Anatomy 0.000 description 1
- 210000004498 neuroglial cell Anatomy 0.000 description 1
- 230000012223 nuclear import Effects 0.000 description 1
- 229940124276 oligodeoxyribonucleotide Drugs 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 210000002741 palatine tonsil Anatomy 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 210000004197 pelvis Anatomy 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920002635 polyurethane Polymers 0.000 description 1
- 239000004814 polyurethane Substances 0.000 description 1
- 239000004800 polyvinyl chloride Substances 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 208000023958 prostate neoplasm Diseases 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 229940034080 provenge Drugs 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 208000037922 refractory disease Diseases 0.000 description 1
- 230000012121 regulation of immune response Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 238000009097 single-agent therapy Methods 0.000 description 1
- 201000010106 skin squamous cell carcinoma Diseases 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 210000001082 somatic cell Anatomy 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 238000011255 standard chemotherapy Methods 0.000 description 1
- 238000011272 standard treatment Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000001360 synchronised effect Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 108010020589 trehalose-6-phosphate synthase Proteins 0.000 description 1
- 229910052721 tungsten Inorganic materials 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 230000004222 uncontrolled growth Effects 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 210000005167 vascular cell Anatomy 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
- A61K39/001189—PRAME
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/00119—Melanoma antigens
- A61K39/001191—Melan-A/MART
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001193—Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; PAP or PSGR
- A61K39/001195—Prostate specific membrane antigen [PSMA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Cell Biology (AREA)
- Developmental Biology & Embryology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US27962109P | 2009-10-23 | 2009-10-23 | |
| US61/279,621 | 2009-10-23 | ||
| US25465709P | 2009-10-24 | 2009-10-24 | |
| US61/254,657 | 2009-10-24 | ||
| US25585009P | 2009-10-28 | 2009-10-28 | |
| US61/255,850 | 2009-10-28 | ||
| PCT/US2010/053879 WO2011050344A2 (en) | 2009-10-23 | 2010-10-22 | Cancer immunotherapy and method of treatment |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2013508415A true JP2013508415A (ja) | 2013-03-07 |
| JP2013508415A5 JP2013508415A5 (https=) | 2013-12-12 |
Family
ID=43415309
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012535437A Pending JP2013508415A (ja) | 2009-10-23 | 2010-10-22 | 癌の免疫療法、および治療の方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20110274723A1 (https=) |
| EP (1) | EP2490713A2 (https=) |
| JP (1) | JP2013508415A (https=) |
| AU (2) | AU2010310468A1 (https=) |
| CA (1) | CA2778707A1 (https=) |
| MX (1) | MX2012004721A (https=) |
| WO (1) | WO2011050344A2 (https=) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2022081492A (ja) * | 2016-05-13 | 2022-05-31 | バイオエヌテック エスエー | 免疫療法に対するタンパク質又はタンパク質のフラグメントの有用性を予測するための方法 |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013044169A1 (en) * | 2011-09-21 | 2013-03-28 | Nestec S.A. | Methods for determining combination therapy with il-2 for the treatment of cancer |
| US9846162B2 (en) | 2012-05-14 | 2017-12-19 | Yale University | Immune biomarkers and assays predictive of clinical response to immunotherapy for cancer |
| WO2014096367A1 (en) * | 2012-12-21 | 2014-06-26 | Servicio Andaluz De Salud | Expression of beta2-microglobulin as a prognostic marker for tumour immune escape and resistance to cancer immunotherapy and a diagnostic biomarker for patient selection for specific gene therapy |
| MX383691B (es) | 2015-03-06 | 2025-03-14 | Beyondspring Pharmaceuticals Inc | Método de tratamiento de cáncer asociado con una mutación de ras. |
| US10155748B2 (en) | 2015-07-13 | 2018-12-18 | Beyondspring Pharmaceuticals, Inc. | Plinabulin compositions |
| WO2017139231A1 (en) | 2016-02-08 | 2017-08-17 | Beyondspring Pharmaceuticals, Inc. | Compositions containing tucaresol or its analogs |
| RU2760348C2 (ru) | 2016-06-06 | 2021-11-24 | Бейондспринг Фармасьютикалс, Инк. | Способ уменьшения нейтропении |
| JP2020503363A (ja) | 2017-01-06 | 2020-01-30 | ビヨンドスプリング ファーマシューティカルズ，インコーポレイテッド | チューブリン結合化合物およびその治療的使用 |
| BR112019015974A2 (pt) | 2017-02-01 | 2020-03-31 | Beyondspring Pharmaceuticals, Inc. | Método para reduzir neutropenia |
| KR20200112881A (ko) | 2018-01-24 | 2020-10-05 | 비욘드스프링 파마수티컬스, 인코포레이티드. | 플리나불린의 투여를 통해 혈소판감소증을 감소시키는 조성물 및 방법 |
| CA3132028A1 (en) * | 2019-03-30 | 2020-10-08 | Biontech Us Inc. | Compositions and methods for preparing t cell compositions and uses thereof |
| TW202241925A (zh) | 2021-01-15 | 2022-11-01 | 德商英麥提克生物技術股份有限公司 | 用於不同類型癌症免疫治療的ｈｌａ展示肽 |
| CA3215047A1 (en) | 2021-04-09 | 2022-10-13 | Lan Huang | Therapeutic compositions and methods for treating tumors |
| US20230190806A1 (en) * | 2021-10-06 | 2023-06-22 | Immatics Biotechnologies Gmbh | Methods of treating metastatic lesions and compositions thereof |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008008541A2 (en) * | 2006-07-14 | 2008-01-17 | Mannkind Corporation | Methods to elicit, enhance and sustain immune responses against mhc class-i restricted epitopes, for prophylactic or therapeutic purposes |
| JP2008510453A (ja) * | 2004-06-17 | 2008-04-10 | マンカインド コーポレイション | エピトープアナログ |
| JP2008526763A (ja) * | 2004-12-29 | 2008-07-24 | マンカインド コーポレイション | 予防又は治療目的のｍｈｃクラスｉ拘束性エピトープに対する免疫応答の誘導、増強及び保持方法 |
| JP2008543315A (ja) * | 2005-06-17 | 2008-12-04 | マンカインド コーポレイション | 癌細胞及び腫瘍間質上に発現される優勢及び亜優勢エピトープに対する多価免疫応答を誘発するための方法及び組成物 |
Family Cites Families (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2606601A (en) | 1948-12-14 | 1952-08-12 | Knoll Associates | Chair having a back rest in the form of a shell-like body |
| US5891955A (en) | 1991-04-16 | 1999-04-06 | Ibf Integrated Business And Finance S.A. | Process for transforming a starting material containing at least two different thermoplastic materials into a new homogenous thermoplastic material |
| DE4143467C2 (de) | 1991-05-17 | 1995-02-09 | Max Planck Gesellschaft | Peptidmotiv und dessen Verwendung |
| US6037135A (en) | 1992-08-07 | 2000-03-14 | Epimmune Inc. | Methods for making HLA binding peptides and their uses |
| ES2276390T3 (es) | 1992-11-05 | 2007-06-16 | Sloan-Kettering Institute For Cancer Research | Antigeno de membrana especifico de la prostata. |
| US5747271A (en) | 1992-12-22 | 1998-05-05 | Ludwig Institute For Cancer Research | Method for identifying individuals suffering from a cellular abnormality some of whose abnormal cells present complexes of HLA-A2/tyrosinase derived peptides, and methods for treating said individuals |
| US5620886A (en) | 1993-03-18 | 1997-04-15 | Ludwig Institute For Cancer Research | Isolated nucleic acid sequence coding for a tumor rejection antigen precursor processed to at least one tumor rejection antigen presented by HLA-A2 |
| US5874560A (en) | 1994-04-22 | 1999-02-23 | The United States Of America As Represented By The Department Of Health And Human Services | Melanoma antigens and their use in diagnostic and therapeutic methods |
| DE4423392A1 (de) | 1994-07-04 | 1996-01-11 | Birsner & Grob Biotech Gmbh | Verfahren zur Identifizierung antigener Peptide |
| US5830753A (en) | 1994-09-30 | 1998-11-03 | Ludwig Institute For Cancer Research | Isolated nucleic acid molecules coding for tumor rejection antigen precursor dage and uses thereof. |
| JPH10512155A (ja) | 1995-02-28 | 1998-11-24 | マックス−プランク−ゲゼルシャフト ツル フェルデルング デアヴイッセンシャフテン エー．ファウ．ベルリン | 癌およびその他の過形成を治療する薬剤 |
| US5698396A (en) | 1995-06-07 | 1997-12-16 | Ludwig Institute For Cancer Research | Method for identifying auto-immunoreactive substances from a subject |
| GB9711957D0 (en) | 1997-06-09 | 1997-08-06 | Isis Innovation | Methods and reagents for vaccination |
| EP2286831A1 (en) | 1997-07-10 | 2011-02-23 | Mannkind Corporation | A method of inducing a CTL response |
| US6994851B1 (en) | 1997-07-10 | 2006-02-07 | Mannkind Corporation | Method of inducing a CTL response |
| US6977074B2 (en) | 1997-07-10 | 2005-12-20 | Mannkind Corporation | Method of inducing a CTL response |
| US20030138808A1 (en) | 1998-02-19 | 2003-07-24 | Simard John J.L. | Expression vectors encoding epitopes of target-associated antigens |
| US6709844B1 (en) | 2000-11-16 | 2004-03-23 | Mannkind Corporation | Avoidance of undesirable replication intermediates in plasmid propagation |
| ATE395930T1 (de) * | 1999-10-22 | 2008-06-15 | Aventis Pasteur | Verfahren zur erregung und/oder verstärkung der immunantwort gegen tumorantigene |
| US20030215425A1 (en) | 2001-12-07 | 2003-11-20 | Simard John J. L. | Epitope synchronization in antigen presenting cells |
| US6861234B1 (en) | 2000-04-28 | 2005-03-01 | Mannkind Corporation | Method of epitope discovery |
| US7334705B2 (en) | 2001-02-26 | 2008-02-26 | Kao Corporation | Container |
| JP2005505242A (ja) | 2001-03-07 | 2005-02-24 | マンカインド コーポレイション | 癌用抗新生血管系調製物 |
| WO2003008537A2 (en) | 2001-04-06 | 2003-01-30 | Mannkind Corporation | Epitope sequences |
| DE10142351A1 (de) | 2001-08-30 | 2003-03-20 | Giesecke & Devrient Gmbh | Initialisieren einer Chipkarte |
| US8029764B2 (en) | 2001-09-07 | 2011-10-04 | The Johns Hopkins University | Methods for detection of colorectal cancer |
| US8637305B2 (en) | 2001-11-07 | 2014-01-28 | Mannkind Corporation | Expression vectors encoding epitopes of target-associated antigens and methods for their design |
| US6706405B2 (en) | 2002-02-11 | 2004-03-16 | Analytical Services & Materials, Inc. | Composite coating for imparting particel erosion resistance |
| US6715905B2 (en) | 2002-06-17 | 2004-04-06 | Birchwood Products Limited | Lighting apparatus |
| EP1394066A1 (en) | 2002-09-02 | 2004-03-03 | Rockwool International A/S | A transport unit with a protective wrapping foil and a method of manipulating said wrapping foil |
| WO2004022709A2 (en) | 2002-09-06 | 2004-03-18 | Mannkind Corporation | Epitope sequences |
| AU2004249254B2 (en) | 2003-06-17 | 2010-07-08 | Mannkind Corporation | Combinations of tumor-associated antigens for the treatment of various types of cancers |
| DE602004028468D1 (de) | 2003-06-17 | 2010-09-16 | Mannkind Corp | Haltung von immunantworten gegen mhc-klasse-i-beschränkte epitope, für prophylaktische oder therapeutische zwecke |
| WO2005013092A2 (en) | 2003-08-01 | 2005-02-10 | Dollars.Com Llc | A system and a method for determining advertising effectiveness |
| WO2005032677A1 (en) | 2003-10-07 | 2005-04-14 | Julian Jamison Kennedy | Method of and apparatus for playing a card game |
| US20060008468A1 (en) | 2004-06-17 | 2006-01-12 | Chih-Sheng Chiang | Combinations of tumor-associated antigens in diagnostics for various types of cancers |
| EP1773402A2 (en) | 2004-06-17 | 2007-04-18 | Mannkind Corporation | Improved efficacy of immunotherapy by integrating diagnostic with therapeutic methods |
| US20060159689A1 (en) | 2004-06-17 | 2006-07-20 | Chih-Sheng Chiang | Combinations of tumor-associated antigens in diagnostics for various types of cancers |
| US7015608B2 (en) | 2004-07-27 | 2006-03-21 | Delco Remy International, Inc. | Method and apparatus to suppress electrical noise in a rotor assembly for an electrical machine |
| EP1838338A2 (en) | 2004-12-29 | 2007-10-03 | Mannkind Corporation | Methods to trigger, maintain and manipulate immune responses by targeted administration of biological response modifiers into lymphoid organs |
| EP1838342A2 (en) | 2004-12-29 | 2007-10-03 | Mannkind Corporation | Methods to bypass cd+4 cells in the induction of an immune response |
| AU2005321898B2 (en) | 2004-12-29 | 2012-07-19 | Mannkind Corporation | Use of compositions comprising various tumor-associated antigens as anti-cancer vaccines |
| WO2006120474A2 (en) * | 2005-05-13 | 2006-11-16 | Oxxon Therapeutics Ltd | Compositions for inducing an immune response against tumor antigens |
| NZ564359A (en) | 2005-06-17 | 2011-09-30 | Mannkind Corp | Analogs of pepetides corresponding to class I MHC-restricted T cell epitopes |
| CN102206216B (zh) | 2005-06-22 | 2014-11-12 | 普莱希科公司 | 作为蛋白质激酶抑制剂的吡咯并[2,3-b]吡啶衍生物 |
| JP4517984B2 (ja) | 2005-09-01 | 2010-08-04 | トヨタ自動車株式会社 | ハイブリッド自動車 |
| US20080199458A1 (en) | 2007-01-19 | 2008-08-21 | Jian-Er Lin | Influenza prevention and treatment composition |
| EP2129389B1 (en) | 2007-02-15 | 2014-10-08 | MannKind Corporation | A method for enhancing t cell response |
| US9469902B2 (en) | 2014-02-18 | 2016-10-18 | Lam Research Corporation | Electroless deposition of continuous platinum layer |
| US9814289B2 (en) | 2015-04-08 | 2017-11-14 | Otter Products, Llc | Protective folio case for an electronic device |
| EP3636238B1 (en) | 2018-10-12 | 2021-04-28 | Liko Research & Development AB | Gates with transition ramps for overhead lifting rails |
| CN113712788B (zh) | 2021-08-13 | 2022-06-28 | 浙江益恒悦医疗科技有限公司 | 智能助行器的防摔控制方法、智能助行器、控制器 |
-
2010
- 2010-10-22 AU AU2010310468A patent/AU2010310468A1/en not_active Abandoned
- 2010-10-22 EP EP10773491A patent/EP2490713A2/en not_active Withdrawn
- 2010-10-22 CA CA2778707A patent/CA2778707A1/en not_active Abandoned
- 2010-10-22 JP JP2012535437A patent/JP2013508415A/ja active Pending
- 2010-10-22 WO PCT/US2010/053879 patent/WO2011050344A2/en not_active Ceased
- 2010-10-22 MX MX2012004721A patent/MX2012004721A/es unknown
- 2010-10-22 US US12/910,778 patent/US20110274723A1/en not_active Abandoned
-
2016
- 2016-03-17 AU AU2016201722A patent/AU2016201722A1/en not_active Abandoned
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2008510453A (ja) * | 2004-06-17 | 2008-04-10 | マンカインド コーポレイション | エピトープアナログ |
| JP2008526763A (ja) * | 2004-12-29 | 2008-07-24 | マンカインド コーポレイション | 予防又は治療目的のｍｈｃクラスｉ拘束性エピトープに対する免疫応答の誘導、増強及び保持方法 |
| JP2008543315A (ja) * | 2005-06-17 | 2008-12-04 | マンカインド コーポレイション | 癌細胞及び腫瘍間質上に発現される優勢及び亜優勢エピトープに対する多価免疫応答を誘発するための方法及び組成物 |
| WO2008008541A2 (en) * | 2006-07-14 | 2008-01-17 | Mannkind Corporation | Methods to elicit, enhance and sustain immune responses against mhc class-i restricted epitopes, for prophylactic or therapeutic purposes |
Non-Patent Citations (2)
| Title |
|---|
| JPN6014050818; Ｊｏｕｒｎａｌ ｏｆ Ｉｍｍｕｎｏｔｈｅｒａｐｙ Ｖｏｌ．３１， Ｎｏ．２, 2008, ｐ．２１５-２２３ * |
| JPN6014050819; Ｖａｃｃｉｎｅ Ｖｏｌ．２７， Ｎｏ．１９, 200904, ｐ．２６０３-２６１５ * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2022081492A (ja) * | 2016-05-13 | 2022-05-31 | バイオエヌテック エスエー | 免疫療法に対するタンパク質又はタンパク質のフラグメントの有用性を予測するための方法 |
Also Published As
| Publication number | Publication date |
|---|---|
| AU2016201722A1 (en) | 2016-04-07 |
| WO2011050344A3 (en) | 2011-11-03 |
| AU2010310468A1 (en) | 2012-05-24 |
| CA2778707A1 (en) | 2011-04-28 |
| EP2490713A2 (en) | 2012-08-29 |
| WO2011050344A2 (en) | 2011-04-28 |
| MX2012004721A (es) | 2012-06-25 |
| US20110274723A1 (en) | 2011-11-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013508415A (ja) | 癌の免疫療法、および治療の方法 | |
| US20060008468A1 (en) | Combinations of tumor-associated antigens in diagnostics for various types of cancers | |
| AU2005258014B2 (en) | Tumor-associated antigen profiles in cancer diagnostics and immunotherapy | |
| Klebanoff et al. | Therapeutic cancer vaccines: are we there yet? | |
| JP5283335B2 (ja) | 各種癌の治療を目的とした腫瘍関連抗原の組合せ | |
| AU2005321898B2 (en) | Use of compositions comprising various tumor-associated antigens as anti-cancer vaccines | |
| US20090131355A1 (en) | Multicistronic vectors and methods for their design | |
| US20060159689A1 (en) | Combinations of tumor-associated antigens in diagnostics for various types of cancers | |
| AU2007272785A1 (en) | Methods to elicit, enhance and sustain immune responses against MHC class-I restricted epitopes, for prophylactic or therapeutic purposes | |
| KR20200040892A (ko) | 알독소루비신 조합 치료 및 방법 (aldoxorubicin combination treatments and methods) | |
| Ghahfarrokhi et al. | Vaccination and personalized cancer vaccines focusing on common cancers in women: A narrative review | |
| Le et al. | Next-generation cancer vaccine approaches: integrating lessons learned from current successes with promising biotechnologic advances | |
| KR20260042221A (ko) | 암 면역요법을 위한 라비린틴-기반 펩티드 및 그의 용도 | |
| Fernandez et al. | Experimental Hematology & Oncology | |
| Leonard et al. | Personalized Cancer Vaccines and Their Efficacy | |
| Nitta et al. | IMT-05 PHASE III RANDOMIZED CLINICAL TRIAL OF AFTV FOR NEWLY DIAGNOSED GLIOBLASTOMA |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20131022 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20131022 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20141202 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20150302 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20150602 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20151201 |